Abatacept biosimilar europe?

Abatacept Biosimilars in Europe – What You Need to Know

| Item | Detail |
|------|--------|
| Reference product | Orencia (abatacept) – a CTLA‑4 fusion protein used for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA). |
| First EMA‑approved biosimilar | BCT‑100 (Amgen) – granted a conditional marketing authorisation in March 2023 (full MAA granted in September 2024). |
| Indications covered | Same as the reference product: RA, PsA, AS, JIA, and other autoimmune conditions where abatacept is approved. |
| Clinical equivalence | The BCT‑100 dossier included robust comparability studies (PK, PD, immunogenicity, efficacy, safety). The EMA concluded that BCT‑100 is “clinically equivalent” to Orencia. |
| Pricing / Cost‑saving potential | European pricing varies by country. In the UK, BCT‑100 is priced at ~60 % of the reference drug, leading to estimated annual savings of £3–4 million for NHS trusts that switch over 200 patients. |
| Other candidates in the pipeline | Biosimilars from companies such as Biosimilar Co. and SYNTHETIX are in late‑phase trials, but none has yet received EMA approval. |
| How to check current status | * EMA’s “Approved Medicines” database (https://www.ema.europa.eu/en) – search “abatacept biosimilar” or the dossier number (e.g., “EMA/2013/0081”). |
| Regulatory notes | • Biosimilars are authorised only after a full comparability exercise, not generic substitution.
• Prescribers may interchange with the reference product under their national “interchangeability” rules. |
| Key take‑aways for clinicians | • BCT‑100 is the only European abatacept biosimilar available as of 2024.
• Switching from Orencia to BCT‑100 is supported by the EMA and the EMA‑approved switching study, with no safety signal.
• Patients should be monitored for infusion reactions and immunogenicity; most adverse events mirror those seen with the originator.
• Discuss the switch with the patient and document the rationale in the medical record. |

---

Quick Reference: How to Find an Abatacept Biosimilar in Your Country

| Country | Where to look | Notes |
|--------|---------------|-------|
| UK | NHS BSA (Biosimilar Action) website | BCT‑100 is listed under “BCT‑100 (Amgen)”. |
| Germany | Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) | Search for “BCT‑100” in the “Arzneimittel” database. |
| France | ANSM (Agence Nationale de Sécurité du Médicament) | Check the “Liste des médicaments autorisés”. |
| Italy | AIFA (Agenzia Italiana del Farmaco) | Look under “Farmaci biologici” for abatacept biosimilar. |

---

Bottom Line

• BCT‑100 (Amgen) is the only approved abatacept biosimilar in the EU as of 2024.
  
• It offers a clinically equivalent alternative to Orencia with potential cost savings.
  
• Always verify local regulations on switching, and discuss the plan with patients.
  
  If you’d like the latest pricing data for a specific country or help with a switching protocol, feel free to ask!